Eric Mull
25Patents
7h-index
57Co-inventors
68Inventor score
Filing activity: Sep 23, 2002 → Jul 9, 2020
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US9308236B2 | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions | Emerging Cross-Sectional Technologies | 24 | Active |
| US9732119B2 | Immunomodulators | Emerging Cross-Sectional Technologies | 14 | Active |
| US9879046B2 | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions | Emerging Cross-Sectional Technologies | 13 | Active |
| US8445490B2 | Compounds for the treatment of hepatitis C | Chemistry; Metallurgy | 11 | Active |
| US9850283B2 | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions | Physics | 9 | Active |
| US9944678B2 | Immunomodulators | Emerging Cross-Sectional Technologies | 8 | Active |
| US10143746B2 | Immunomodulators | Human Necessities | 8 | Active |
| US10538555B2 | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions | Emerging Cross-Sectional Technologies | 7 | Active |
| US10144706B2 | Compounds useful as immunomodulators | Chemistry; Metallurgy | 7 | Active |
| US8765944B2 | Compounds for the treatment of hepatitis C | Chemistry; Metallurgy | 7 | Active |
| US10450347B2 | Immunomodulators | Emerging Cross-Sectional Technologies | 6 | Active |
| US8586584B2 | Compounds for the treatment of hepatitis C | Chemistry; Metallurgy | 6 | Active |
| US10358463B2 | Immunomodulators | Emerging Cross-Sectional Technologies | 6 | Active |
| US8741884B2 | Compounds for the treatment of hepatitis C | Human Necessities | 4 | Active |
| US6900205B2 | 1,8-Naphthyridine derivatives and their use to treat diabetes and related disorders | Chemistry; Metallurgy | 4 | Expired |
| US7109196B2 | 1,8 Naphthyridine derivatives and their use to treat diabetes and related disorders | Chemistry; Metallurgy | 4 | Expired |
| US8957203B2 | Hepatitis C virus inhibitors | Human Necessities | 2 | Active |
| US10745382B2 | Compounds useful as immunomodulators | Emerging Cross-Sectional Technologies | 2 | Active |
| US11066445B2 | Immunomodulators acting as antagonists of PD-1 | Human Necessities | 2 | Active |
| US10745384B2 | Indazole derivatives as αv integrin antagonists | Chemistry; Metallurgy | 1 | Active |
| US11028071B2 | Indazole derivatives as alpha v integrin antagonists | Chemistry; Metallurgy | 0 | Active |
| US9527885B2 | Hepatitis C virus inhibitors | Human Necessities | 0 | Active |
| US9598433B2 | Hepatitis C virus inhibitors | Chemistry; Metallurgy | 0 | Active |
| US9624245B2 | Macrocyclic compounds as HCV entry inhibitors | Chemistry; Metallurgy | 0 | Active |
| US9499550B2 | Hepatitis C virus inhibitors | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.